Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
AbbVie, Bristol-Myers Squibb, Genentech, Janssen and Merck & Co. have all advanced anti-tau candidates into Phase I trials in the hunt for drugs that can modify the course of Alzheimer disease.
Melissa Paoloni, an architect of the I-SPY 2 trial at QuantumLeap Healthcare Collaborative, discusses the evolution of one of the first adaptive, umbrella trials.
Traditional cytotoxic chemotherapies have been the mainstay of treatment for bladder cancer for decades, but targeted biologics are now becoming available. This article analyses the late-stage pipeline for bladder cancer and the impact of new drugs in this rapidly growing market.
Fragment-based methods have made substantial contributions to drug discovery in the past 20 years, particularly for challenging targets. Erlanson and colleagues discuss progress in the field, key aspects such as the design of fragment libraries and the choice of screening technique, and how current challenges in fragment-based drug discovery might be overcome.
The focus of cardiovascular research has changed over the decades, and non-myocytes, including fibroblasts, are becoming increasingly central to our understanding of cardiac function. Kohl and colleagues discuss cardiac fibroblasts, their origins and their expanding roles in homeostasis and tissue repair, and highlight opportunities for therapeutic intervention.
Adipose tissue may become severely dysfunctional during obesity, resulting in disrupted metabolic homeostasis and ultimately type 2 diabetes. Here, Scherer and colleagues provide an overview of adipose tissue development, function and homeostasis, focusing on emerging potential strategies for targeting this organ in the treatment of obesity-associated diabetes.
